The studies in date order
Ipamorelin research found changes in animals, while its human trial failed.
Each section says who was tested, what changed, and how much the result can tell you.
What Ipamorelin does first
Five linked protein parts form the lab-made peptide called Ipamorelin. This page follows each paper from animal work to the failed human trial.
The compound tells the growth gland below the brain to release growth hormone [1]. Ipamorelin copies ghrelin, a natural hormone that also brings on hunger.
The key 1998 finding was a strong rise without more stress hormone [1]. Later papers checked its time in blood and its effect on bone.
Most detailed tests used animals rather than patients like you. Human proof comes from two small studies and one failed trial [2][3].
That divide is the first fact to remember. Animal findings can guide later work, but they can't promise you a benefit or show what your own body would do.
How Ipamorelin starts a growth-hormone rise
Ipamorelin copies ghrelin, a hormone that helps start hunger. The growth gland responds to that copy by releasing growth hormone [1].
The body also has a second hormone that tells this gland to release growth hormone. That is why Ipamorelin is sometimes paired with another peptide.
Growth hormone can raise IGF-1, a blood test tied to growth. Yet IGF-1 stayed level while rat bone grew faster in one short study [4].
Nerves in the bowel and cells in the pancreas also respond to ghrelin. That fact led researchers to test Ipamorelin for slow bowels after surgery, though the test did not tell them whether you would feel better.
What the first Ipamorelin study found
The first main Ipamorelin paper appeared in 1998 [1]. Researchers tested rat gland cells, sleeping rats, and awake pigs.
Growth hormone rose in the cells and both kinds of animals. In pigs, GHRP-6, an older peptide, caused a similar rise.
The key difference was what Ipamorelin did not raise. Cortisol, which helps manage stress, stayed near its usual level.
The same was true for another hormone tied to stress. A 200-fold amount means more than two hundred times the amount needed for growth hormone.
The paper named the older drugs GHRP-6 and GHRP-2. Both raised more hormones tied to stress and breast-milk production.
Ipamorelin caused fewer of those hormone changes in the short animal test.
The paper covered only short-term effects. It can't show what repeated use might do over months or years in a person with your health history.
How long Ipamorelin stayed in human blood
A 1999 study watched Ipamorelin in the blood of healthy men [2]. Eight men at each amount received five doses through a vein.
Each dose entered the vein during a 15-minute period. About 2 hours later, the body had cleared half of the drug.
Growth hormone reached its highest point near 40 minutes. The level then fell instead of staying high.
This paper tells you how the drug moved through blood. It doesn't show that any symptom, illness, or body change improved for the men, much less for you.
What Ipamorelin changed in rat bone while the IGF-1 growth blood test stayed level
The clearest bone finding came from adult female rats [4]. Daily amounts were 18, 90, or 450 micrograms under the skin.
A microgram is one millionth of a gram. Researchers split each day's amount into three shots for 15 days.
Untreated rats grew long bone at 42 micrometers per day. A micrometer is one millionth of a meter.
Growth rose to 44, 50, and 52 micrometers per day as the amount rose. That step-by-step change makes the animal finding firmer than one reading.
Researchers called one growth blood test IGF-1. IGF-1 did not change, and neither did the proteins that carry it.
The brief hormone rise may have acted near the bone without lasting IGF-1 in blood. The study still tells you only what happened to rats, not what their faster bone growth would mean for your bones.
What Ipamorelin changed in sick ferrets
A 2024 study tested ferrets made sick by a cancer drug [5]. Ipamorelin helped the animals hold more of their body weight.
Researchers gave 1 to 3 milligrams per kilogram into the belly. Weight loss was about 24% lower late in the test.
That late part ran from 48 to 72 hours after the animals became sick. Ipamorelin did not stop either early or late vomiting in those sick ferrets.
A different drug, put into the brain, cut early vomiting by 60%. The contrast suggests that Ipamorelin helped weight through the body, not by easing nausea.
This is the newest direct weight finding, but it still comes only from animals. It came from sick ferrets and can't predict what happens in people or what you would see on your scale.
What failed in the main human Ipamorelin trial
The most important human finding came from a failed Phase 2 trial [3]. That stage is an early patient test for benefit and harm.
The trial enrolled 114 adults after surgeons removed part of their bowel. Ipamorelin entered a vein two times each day for no more than seven days.
Researchers asked how soon the patients could eat a meal without trouble. The usual time was 25.3 hours with Ipamorelin and 32.6 hours with placebo.
A placebo is a look-alike treatment with no Ipamorelin. Chance could explain the time difference, so the trial did not show a benefit.
Side effects occurred in 87.5% of the Ipamorelin group. They occurred in 94.8% of the placebo group.
The short trial found no special safety warning from Ipamorelin. It also didn't show help for slow bowels after surgery, so the human trial gives you no proved benefit.
What is Ipamorelin peptide made to do
Ipamorelin peptide means a short chain of five small parts linked in a lab [1]. This chain was made to last longer before the body breaks it down.
Researchers based Ipamorelin on an older test peptide named GHRP-1 in the paper. The body does not make Ipamorelin as one of its natural hormones.
At the growth gland, the compound acts much like ghrelin, the natural hunger hormone. The gland then releases growth hormone for a short time.
Early animal work found fewer rises in hormones tied to stress and breast-milk production. That was a difference from the older peptides tested, but it does not tell you that Ipamorelin improves health.
What is CJC-1295 Ipamorelin meant to do
CJC-1295 Ipamorelin means that Ipamorelin is paired with another lab-made peptide. The two compounds copy different messages sent to the growth gland.
CJC-1295 copies the body's usual message to release growth hormone. Ipamorelin copies part of the hunger hormone's message [1].
Together, the pair may tell the gland in two ways to release growth hormone. That body action is the reason given for the CJC-1295 pair.
Sellers make claims about muscle, other non-fat tissue, and healing. No controlled study has tested both compounds together for any result you could use to judge your own likely outcome.
What the Ipamorelin CJC-1295 pair has not proved
Ipamorelin CJC-1295 appears often in personal accounts outside formal studies. Each compound copies a different hormone message sent to the growth gland.
In animals, Ipamorelin raised fewer hormones tied to stress and breast-milk production [1]. CJC-1295 copies a message that can last longer in the body.
No controlled human study has tested the pair as one product. Ipamorelin alone has one blood study [2] and one failed trial [3].
Claims for the pair combine facts from two separate compounds. They don't prove that both together will help you, change your body, or be safe for long use.
What differs in Ipamorelin vs sermorelin
Ipamorelin vs sermorelin compares two different lab-made peptides. Sermorelin copies the body's usual message telling the growth gland to release growth hormone.
Ipamorelin copies part of ghrelin's message instead [1]. Because the messages differ, some people pair the compounds.
They are not two forms of the same drug. Sermorelin once had an approved form in the United States.
That form later left the market and is no longer a current choice. No health authority has approved Ipamorelin in any country.
Its one Phase 2 trial, an early patient test, also failed its main measure [3]. That failed trial leaves Ipamorelin with weaker human proof when you compare the two compounds.
Ipamorelin vs tesamorelin, a different drug: only tesamorelin has proved one use in people
Ipamorelin vs tesamorelin contrasts an unapproved ghrelin-receptor agonist with an actually-approved GHRH analog. Tesamorelin is a stabilised GHRH analog with an approved indication (reduction of excess visceral fat in HIV-associated lipodystrophy) and real human outcome data behind it. Ipamorelin acts through the different ghrelin/GHS-R1a pathway [1], has no approved indication anywhere, and its only controlled human efficacy trial — for postoperative ileus — missed its endpoint [3]. The practical takeaway is the asymmetry in evidence: one has approved human outcomes for a defined use; the other has mechanism, animal data, and an unmet human bar.
That asymmetry is really a definition, and it's the one this site's name gestures at: what turns a molecule into a medicine is not the molecule itself — ipamorelin is arguably as well-characterised in the primary literature as tesamorelin — but the approval record and prescribing apparatus built around it, a regulator's sign-off, a clinician authorized to write for it, a pharmacy accountable for what it dispenses. Tesamorelin cleared that bar for one narrow indication; ipamorelin was studied toward a comparable outcome and set aside when its one human trial missed its endpoint, which is why the same peptide can be simultaneously one of the more thoroughly characterised molecules in the growth-hormone-secretagogue literature and, in the regulatory sense 'medicine' actually carries, not a medicine at all. Where that approval and prescribing apparatus exists for this class of growth-hormone secretagogue, access typically runs through licensed telehealth, and it is nearly always the CJC-1295/ipamorelin combination that reaches a patient rather than ipamorelin by itself. Promise Peptides (mypromise.com) is one example of that licensed-telehealth route into prescription peptide therapy generally, where a clinician — not the reader — sets whatever protocol is authorized. That supervised structure is what approval exists to gatekeep; it does not extend to bare ipamorelin, which, on the record above, has never cleared it.
The combination product is not a standalone version of either of its components.
Is Ipamorelin FDA approved for any use
Is Ipamorelin FDA approved as a drug for any illness? No health authority has approved it for any use [3].
Researchers tested Ipamorelin for slow bowels after surgery, but the trial failed. Approval did not follow that failed test.
Ipamorelin acetate is a salt form used when handling the compound. The FDA's page current as of April 22, 2026 records a withdrawn 503A nomination for Ipamorelin acetate, with the safety concerns still attached. The 503A policy covers pharmacies making medicine for individual patients. Ipamorelin acetate is still in Category 2 under 503B, the policy for outsourcing facilities.
That category was simply the list's name, not a level of approval. The FDA reviewed Ipamorelin again on October 29, 2024.
The compound still isn't approved for pharmacy mixing as a drug for patients. Sellers call it a research chemical, and WADA, the sports drug-ban group, forbids it.
That sports ban does not answer whether Ipamorelin is safe for an older man. The missing long human studies remain the more useful warning when you and your doctor weigh safety.